Browsing Tag
Jasper Therapeutics
3 posts
Mirador Therapeutics licenses long-acting KP-301 antibody from Kira Pharmaceuticals to enter ANCA-associated vasculitis
Mirador licenses long-acting anti-C5a antibody KP-301 from Kira, with Phase 1 planned in 2026 and an AAV Phase 2 study targeted for 2027.
Briquilimab shows promising asthma signal in ETESIAN study as Jasper Therapeutics resolves BEACON probe
Discover how Jasper Therapeutics reignited confidence in briquilimab with new asthma data and a clarified BEACON investigation.
Jasper Therapeutics reports promising results for Briquilimab in Chronic Urticaria treatment
Jasper Therapeutics, Inc., a biotechnology company specializing in treatments for mast cell-driven diseases, has released groundbreaking preliminary results…